**Genscript Biotech Corporation**
**金斯瑞生物科技股份有限公司** *
*(Incorporated in the Cayman Islands with limited liability)*
**(Stock code: 1548)**

# VOLUNTARY ANNOUNCEMENT
# PRESENTATIONS ON COMPANY UPDATES AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

The board (the "**Board**") of directors (the "**Directors**") of the Genscript Biotech Corporation (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Company participates in the 42nd Annual J.P. Morgan Healthcare Conference (the "**Conference**"), and the company updates of each of the Company and Legend Biotech Corporation, a non-wholly owned subsidiary of the Company, whose shares are listed by way of American Depositary Shares on the Nasdaq Global Select Market in the United States, will be presented at the Conference (the "**Presentations**"). For details, please refer to the attached Presentations.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

**This announcement and the Presentations contain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on the beliefs as well as assumptions made by and information currently available to the management of the Company. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such expectations could be affected by various different factors. Any forward-looking statements contained in this announcement and the Presentations speak only as of the date of this announcement. The Group specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise**.

**Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.**

By Order of the Board
**Genscript Biotech Corporation**
**MENG Jiange**
*Chairman and Executive Director*

Hong Kong, 10 January 2024

*As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.*

* *For identification purposes only*

HK. 1548

# GenScript Biotech Corporation

Make People and Nature Healthier through Biotechnology

# Disclaimer*

## Forward-Looking Statement

This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, and our ability to protect our clients’ intellectual property. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section.

## Use of Adjusted Financial Measures (Non-HKFRS Measures)

We have provided adjusted net profit, which excludes the share-based compensation expenses are not required by, or presented in accordance with, HKFRS. We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing underlying business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual and non-recurring items that we do not consider indicative of the performance of our business. However, the presentation of these non-HKFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with HKFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under HKFRS, or as being comparable to results reported or forecasted by other companies.

# Content

- Company Overview
- Pioneering in Cell and Gene Therapy
- From DNA to Synthetic Biology
- Key Investment Highlights



# Mission

## Make People and Nature Healthier through Biotechnology

**2002**

Founded in New Jersey, US

**2013**

Established Bestzyme

(Industrial Synthetic Biology Product Segment)

**2014**

Founded Legend Biotech

(Cell Therapy Segment)

**2015**

GenScript was listed on HKEX

(stock code: HK.1548)

**2018**

Established Biologics CDMO Segment

(GenScript ProBio)

**2022**

CARVYKTI® granted approvals by US FDA, EC and Japan MHLW

**2023**

CRISPR GMP Facility Launched

# Financial Snapshot

## Group Revenue ($M)




## CARVYKTI® Sales ($M)




- Two decades of sustained business growth
- Solid Cash Position

- Leading gene synthesis provider in market*
- Seeking emerging opportunities in Cell and Gene Therapy and Synthetic biology

- For Cilta-cel program (Commercial name: CARVYKTI® ), Legend entered into global collaboration agreement with J&J
- CARVYKTI®— Asset with $5B+ annual peak sales potential

*Based on QY research

# Global Footprint[1]

~6,500 Global employees

~800 R&D team

~40% Master's degree or higher

in 100+ countries and regions

with 200,000+ customers[2]




1. As of June 30, 2023
2. Exclude patients who receive CAR-T therapy

# Pioneering in Cell and Gene Therapy

Customized Research

Clinical Manufacturing

Unmet Medical Needs

# Global Leading Gene Synthesis Provider

**20 Years +**

of experience

**200,000+**

customers from over 100 countries

**3,000,000+**

synthetic genes delivered

## Automated Gene Synthesis Platform

- *Efficiency doubled compared to manual[1]*
- *Full lifecycle automation from order to shipping*

## Efficient Plasmid Extraction Platform

- *100% full insert sequence accuracy-AAV ITR & Poly A guarantee*
- *All grades and scales covered[2]*

## GenSmart™ Intelligent Platform

- *200+ factors screened & validated in codon optimization*
- *1,900+ citations in multiple research fields*

## GenTitan™ Platform

- *Oligo pool - 8 Million Oligos on 1 Chip*
- *Gene Fragments - Higher acceptance rate and lower unit price*

1. Based on Kbp/FTE
2. Deliver plasmid DNA for basic research to animal study. GenScript ProBio provides GMP grade plasmid. Produce Plasmid DNA from microgram to gram level

# Supporting CRISPR Genomic Medicines*

**100+ Batches**
GMP products

**20+**
successful audits

**30**
IND projects

**6**
IND approvals

## Services

### Synthetic CRISPR sgRNA
- *GMP grade*
- *From mg to grams*
- *400 batches/ year*

### HDR Knock-in Templates
- *GMP grade*
- *From mg to grams*
- *100 batches/ year*

### Cas Nucleases
- *GMP grade*
- *Cas9, Cas12a and Cas13a*

### CRISPR/Cas Plasmids
- *More than 20,000 lentiCRISPRv2 plasmids*

### CRISPR Screening Libraries
- *GeCKO libraries for genome-wide knockout*
- *CRISPR Synergistic Activating Mediator (SAM)*

### CRISPR Cell Lines
- *From design to characterization*

## Facility

- ~421,000 sq.ft
- 17 manufacturing lines



* Accumulated track record

# Leading Plasmid CDMO

## Rapid Turnaround

- *Plasmid Quality Tailored to your application*
- *GMPro: 3 wks to deliver, 4-5 wks shorter than industrial average*
- *GMP: 8 wks to deliver, 3-4 mths shorter than industrial average*

## Technological Advantage

- *7 patents[1]*
- *LVV application: Proprietary backbone and helpers with FDA Drug Master File*
- *AAV application: Proprietary AAV system and E. coli strain*
- *Proprietary manufacturing process for linearized DNA*

## Global Outreach[1]

- *38 global IND approvals from NMPA&FDA&PMDA&MFDS*
- *7 IND approvals from FDA; 4+ IND from FDA by US clients in 2023*
- *GMP facility pass PAI by Indonesia FDA*

1. As of Nov.2023

# Global CGT GMP MFG Capacity

- *State-of-the-art plasmid facility with 220,000 sq.ft*
- *Total 16 GMPro™ and GMP plasmid manufacturing lines*
- *Has both single-use and stainless steel systems, from 5L to 500L*
- *Separated and dedicated function areas with unidirectional flow and airlocks within production area*
- *In compliance with cGMP and follow ICH, FDA, and EMA Guidance*


Piscataway, New Jersey

## Plasmid PD Lab (In Service)

- 1L-10L plasmid production


Zhenjiang, China

## Integrated Plasmid Facility (In Service)

- GMPro™ and GMP plasmid manufacturing
- From preclinical to clinical and commercial GMP manufacturing
- 10L-500L scale with SS and SUF systems


East Hanover, New Jersey
2024 Q3

## Integrated Plasmid Facility (To be launched)

- GMPro™ 1L-10L plasmid production
- GMP 30-300L plasmid manufacturing

# Cilta-cel: Potential Best-in-Class Clinical Profile

**1L**
**~160k pts[1,2]**

CARTITUDE-5 (1L MM, transplant not intended): enrollment to be completed by 1H 2024

CARTITUDE-6 (1L MM, transplant eligible): enrollment began in 2H 2023

**2~4L**
**~80k pts[1,3]**

CARTITUDE-4: Cilta-cel vs SOC
- 12-month PFS rate: 76% vs 49%
- Best HR (0.26) in MM vs SOC

Potential to be a new SoC for patients with lenalidomide-refractory myeloma after first relapse

Expect approvals in 2L-4L RRMM in the US and EU in 2024

**4L**
**~22k pts[1]**

CARTITUDE-1:
- 98% ORR; 83% sCR
- 34.9mo mPFS; mOS not reached at 3-yr FU

Exceptional efficacy for BCMA-directed CAR-T in heavily pretreated patients with R/R MM

Approved in the US, EU and Japan for late line MM treatment in 2022

1. Addressable patient population across 3 major markets: US, Europe, Japan
2. ~160K patients for 1L+ (all lines inclusive)
3. ~80K patients for 2L and beyond

# CARVYKTI® Commercialization and Manufacturing Capabilities

CARVYKTI™ (ciltacabtagene autoleucel) Suspension for IV Infusion

**176%** Q3 23 YoY sales growth

**April 5,2024** sBLA PDUFA target date

**$5B+** Potential peak sales

## State-Of-The-Art CARVYKTI® Manufacturing Facilities

- Obelisc Facility in Ghent, Belgium received license from the Federal Agency for Medicines and Health Products in Belgium for clinical supply manufacturing
- Awaiting Investigational Medicinal Product Dossier approvals from local authorities
- Anticipate manufacturing cilta-cel at Ghent for clinical use in January 2024 and commercial use in 2H 2024

## J&J In-House Lentivirus Facilities*

- J&J facility in Switzerland now producing Lentivirus in-house
- All commercial Lentivirus now produced in-house and we are self-sufficient
- Additional Lentivirus supply is expected to be available from J&J facilities in US and Netherlands in 2024 and 2025, respectively

## Novartis as CMO for Clinical Supply

- Signed CMO agreement with Novartis during Q2 2023
- On track to produce clinical materials in 1H 2024

*All the Lentivirus facilities are owned by J&J.

# From DNA to Synthetic Biology

Enabling Tools

Integrated Systems

Enabled Products

# Exploring More Possibilities in SynBio Frontier




## Protein Engineering

- Advanced Gene Editing Technologies-CRISPR/Cas9 to edit multiple genes simultaneously
- Bioinformatics platform powered by AI—In-house developed codon optimization

## Industrial Expression System

- Six industrial expression platforms
- Continuing optimizing the genetic and regulatory processes within cells or microorganisms

## Solid Commercialization Capabilities

- Automatic production line
- Multi-certificated with ISO22000/FSSC22000, KOSHER, FAMI-QS, etc.
- End products serve for diversified industrial application scenarios

# Key Investment Highlights

## 01 Life Science

- A $10B+ addressable market
- 20 years of consecutive growth
- Growing with research communities by providing innovative life science services and products

## 02 SynBio & Enzyme

- Potential 20%+ enzyme business growth
- Integrated R&D and manufacturing platform to boost breakthroughs in SynBio products

## 03 Biologics CDMO

- Unique offering of plasmid and virus vector in CGT applications
- Incoming U.S. plasmid manufacturing facilities to boost global expansion
- Proven track record in Antibody and CGT CDMO

## 04 Cell Therapy

- $5B+ potential CARVYKTI ® annual peak sales
- Multiple pipelines to boost further growth
- Global powerhouse by leveraging external collaborations

HK. 1548

# GenScript Biotech Corporation

Make People and Nature Healthier through Biotechnology

## Thanks

For More Information: https://www.genscript.com/

# Legend Biotech Corporate Presentation

JANUARY 2024

LEGEND BIOTECH

This presentation is for investor relations purposes only – Not for product promotional purposes

# Disclaimer

This presentation has been prepared by Legend Biotech Corporation ("Legend Biotech" or the "Company") solely for information purpose and does not contain all relevant information relating to the Company.

The safety and efficacy of the agents and/or uses under investigation discussed in this presentation have not been established, except to the extent specifically provided by marketing authorizations previously received from relevant health authorities. Further, for investigational agents and/or uses, the Company cannot guarantee health authority approval or that such agents and/or uses will become commercially available in any country.

Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Legend Biotech's own internal estimates and research. While Legend Biotech believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. While Legend Biotech believes its internal research is reliable, such research has not been verified by any independent source.

Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995.

These statements include, but are not limited to, statements relating to Legend Biotech's strategies and objectives; statements relating to CARVYKTI®, including Legend Biotech's expectations for CARVYKTI®, including manufacturing expectations for CARVYKTI®; and statements about regulatory submissions for CARVYKTI®, and the progress of such submissions with the FDA, the EMA and other regulatory authorities; and expected results and timing of clinical trials; Legend Biotech's expectations for LB2102 and its potential benefits; Legend Biotech's ability to close the licensing transaction with Novartis and potential benefits of the transaction; Legend Biotech's expectations on advancing their pipeline and product portfolio; and the potential benefits of Legend Biotech's product candidates. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward- looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to Legend Biotech's patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; competition in general; government, industry, and general product pricing and other political pressures; the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation; as well as the other factors discussed in the "Risk Factors" section of Legend Biotech's Annual Report on Form 20-F filed with the Securities and Exchange Commission (SEC) on March 30, 2023 and Legend Biotech's other filings with the SEC.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this presentation as anticipated, believed, estimated or expected. Any forward-looking statements contained in this presentation speak only as of the date of this presentation. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

# Legend Biotech Highlights

**9** Years Since Inception

One of the earliest companies to engineer CAR-T cells for the BCMA protein

**1,800+**

Employees

**~300** Dedicated to R&D

**1**

Marketed Product: CARVYKTI® (ciltacabtagene autoleucel; cilta-cel)[1,2]

**8**

Pipeline Programs Covering:

- Hematologic malignancies
- Solid tumors

**3**

Core Technologies:

- CAR-T, including universal CAR
- CAR-NK
- γδ – T[3]

**6**

Global Manufacturing Sites for CARVYKTI®:

- 1 site in US
- 2 sites in EU (Ghent)[4]
- 2 sites in China[4]
- 1 Novartis site (CMO)

**$1.4 Bn**

in Cash and Cash Equivalents, Deposits, and Short-Term Investments[5]

1. In collaboration with J&J; 2. Please read Prescribing Information for full safety information: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/CARVYKTI-pi.pdf;
3. gamma delta T cells; 4. EU and China manufacturing site construction is in progress; 5. As of September 30, 2023

# CARVYKTI® Uptake Continues

Continued market penetration, geographic expansion, and population in earlier lines of treatment represent significant growth drivers and opportunity




| | YOY GROWTH | Q3'23 OVER Q2'23 GROWTH |
|---|---|---|
| U.S. | 155% | 23% |
| EU | N/A | 300% |
| GLOBAL | 176% | 30% |

- U.S. QoQ growth of 23% primarily driven by:
  - Successful launch execution
  - Deepening market share
  - Capacity improvements
  - Increased number of activated U.S. treatment sites to 64
- EU QoQ growth of 300% due to launch in Germany

# A New Standard for CAR-T Launches

## CARVYKTI® - INDUSTRY LEADING EARLY LAUNCH PERFORMANCE

## FIRST SIX QUARTERS OUTPERFORMING HISTORICAL CAR-T LAUNCHES




Data Source: Companies' public filings.

# Pioneer and Leader in Cell Therapy

# A Fully Integrated Global Leader in Cell Therapy

## MARKET-LEADING MULTIPLE MYELOMA (MM) CAR-T THERAPY

- sBLA and Type II variation to support label expansion accepted by U.S. FDA (PDUFA target action date of April 5, 2024) and EMA, respectively
- Application supported by first randomized Phase 3 study for cilta-cel use as early as 2L

## COMPELLING MM PROGRAM AND AN INNOVATIVE PIPELINE

- Cilta-cel demonstrates consistently deep and durable responses across clinical trials with a manageable safety profile
- De-risked Phase 3 Programs present opportunities to unlock value in earlier line MM indications
- Additional pre- / early clinical stage programs targeting both hematologic and solid tumor indications

Johnson&Johnson

## MANUFACTURING EXPERTISE DEVELOPED THROUGH GLOBAL COLLABORATION WITH J&J*

- Cilta-cel development collaboration combines Legend's leadership in cell therapy with J&J's* expertise in global drug development
- Expanding manufacturing capacity in the US and China and building large-scale manufacturing facilities in the EU

## INTEGRATED CELL THERAPY PLATFORM

- In-house antibody generation and CAR-T specific functional screening technologies
- Early clinical proof-of-concept, working with KOLs in China, the US and globally
- Autologous and allogeneic platforms enable sustainable growth and scalability to address future commercial demand
- Strong intellectual property position

KOL, key opinion leaders

**Legal entity to the agreement is Janssen Biotech, Inc.; collaboration established in December 2017*

# Our Differentiated R&D Approach

Potential best-in-class proprietary technology platforms and end-to-end capability

**Armoring strategy for solid tumors**

Multiple armored CAR-T strategies to overcome challenges in treatment of solid tumors

**Antibody screening & engineering**

In-house antibody generation and CAR-T-specific functional screening technologies

**Diverse platform for allogeneic treatments**

Diverse allogeneic platforms, including non-gene editing universal CAR-T and NK

### Antibody Screening Platforms

High-throughput antibody screening and engineering capability, including single-domain antibodies generated from llama and conventional antibodies

### Binding Domain Selection and Construct Design

Proprietary methodology to optimize the selection of binding domains and design CAR-T constructs with two or more antigen-binding domains

### Pre-clinical Validation

Robust *in vitro* and *in vivo* screening platforms to prioritize pipeline assets

### Clinical Proof of Concept

Efficient clinical translation with IND and IIT studies, working with KOLs in US and China

# Legend and J&J Global Collaboration

Worldwide collaboration and license agreement to develop and commercialize cilta-cel


**2018**

Upfront Payment
**$350 million**
Q1 2018

First Milestone
**$25 million**
Dec 2018

**2019**

Second Milestone
**$25 million**
Jul 2019

Third Milestone
**$30 million**
Jul 2019

**2020**

Fourth Milestone
**$30 million**
Jan 2020

Fifth Milestone
**$75 million**
December 2020

**2021**

Sixth Milestone
**$15 million**
May 2021

**2022**

9th Milestone
**$50 million**
April 2022

7th/8th Milestones
**$50 million**
January 2022

**2023**

Eligible for Potential Additional Milestone Payments

10th/11th Milestones
**$35 million***
August 2023

*On August 3, 2023, Legend Biotech received a payment in the amount of $15 million for the EMA's acceptance of the Type II Variation Application for CARVYKTI®, in accordance with Legend Biotech's license and collaboration agreement with Janssen (Janssen Agreement). In September 2023, Legend Biotech received a milestone payment of $20 million in connection with the FDA's acceptance of the sBLA, in accordance with the Janssen Agreement.

# Global Manufacturing Footprint

## US Facilities

**Raritan, NJ**

**US / EU / JP / ROW Launch/ Commercial Site for CARVYKTI®**

✓ GMP Operational

**Somerset, NJ**

**US / EU / JP Legend Clinical Supply Site for Pipeline Programs**

## EU Facilities

**Ghent, Belgium**

**Future Commercial Site for CARVYKTI®**

- Construction ongoing

**Ghent, Belgium**

**Future Commercial Site for CARVYKTI®**

- Clinical production scheduled in January 2024 and commercial production expected in 2H 2024

## China Facilities

**Nanjing**

**Legend China Clinical Supply Site for Pipeline Programs & Potential China Launch Site for CARVYKTI®**

✓ GMP Operational


**Nanjing 75-acre**

**Potential Future Commercial Site for CARVYKTI®**

- Construction ongoing

# Expanding Our Manufacturing Capabilities

Bringing cell therapies to market given unique challenges to improve overall supply

## State-Of-The-Art CARVYKTI® Manufacturing Facilities

- Obelisc Facility in Ghent, Belgium received license from the Federal Agency for Medicines and Health Products in Belgium for clinical supply manufacturing
- Awaiting Investigational Medicinal Product Dossier approvals from local authorities
- Anticipate manufacturing cilta-cel at Ghent for clinical use in January 2024 and commercial use in 2H 2024

## J&J In-House Lentivirus Facilities*

- J&J facility in Switzerland now producing Lentivirus in-house
- All commercial Lentivirus now produced in-house and we are self-sufficient
- Additional Lentivirus supply is expected to be available from J&J facilities in US and Netherlands in 2024 and 2025, respectively

## Novartis as CMO for Clinical Supply

- Signed CMO agreement with Novartis during Q2 2023
- On track to produce clinical materials in 1H 2024

*All the Lentivirus facilities are owned by J&J.

# Out-licensing Deal with Novartis on CAR-T Therapies Targeting DLL3

- Legend announced on Nov 13, 2023 an exclusive, global license agreement with Novartis to advance certain DLL3-targeted CAR-T therapies, including LB2102, an investigational therapy for small cell lung cancer.
- Legend announced on Jan 3, 2024 closing of the license transaction.

AN UPFRONT PAYMENT

$100M

ELIGIBLE MILESTONE PAYMENTS

*up to*

$1.01B

*Plus*

Tiered Royalties on Net Sales

POTENTIAL APPLICATION OF

T-Charge™ Platform of Novartis

FOR MANUFACTURING

DLL3 DEVELOPMEMT AND COSTS

→ Legend to conduct Ph1 for LB2102 in the US

→ Novartis to conduct all other development for the licensed products

# Our Pipeline

Global | US | China

| PRECLINICAL | PHASE 1 | | | PHASE 2 | PHASE 3 |
|---|---|---|---|---|---|
| NSCLC<br>(GPC3)<br>Autologous | SCLC‡§<br>(DLL3)<br>Autologous<br>NCT05680922 | RRMM (BCMA)<br>LEGEND-2†<br>Autologous<br>NCT03090659 | HCC†<br>(GPC3)<br>Autologous<br>NCT05352542 | RRMM (BCMA)*<br>CARTIFAN-1<br>Autologous<br>NCT03758417 | RRMM (BCMA)*<br>1-3 Prior Lines<br>CARTITUDE-4<br>Autologous<br>NCT04181827 |
| COLORECTAL<br>(GCC)<br>Autologous | GASTRIC &<br>ESOPHAGEAL &<br>PANCREATIC‡<br>(CLAUDIN 18.2)<br>Autologous<br>NCT05539430 | MM†<br>(BCMA)<br>Allogeneic CAR-NK<br>NCT05498545 | NHL† /ALL†<br>(CD19 X CD20 X<br>CD22)†<br>Autologous<br>NCT05318963<br>NCT05292898 | RRMM (BCMA)*<br>CARTITUDE-1<br>Autologous<br>NCT03548207 | NDMM (BCMA)*<br>Transplant Not<br>Intended 1L<br>CARTITUDE-5<br>Autologous<br>NCT04923893 |
| | MM†<br>(BCMA)<br>Allogeneic – CAR-γδ T<br>NCT05376345 | | | MM (BCMA)*<br>CARTITUDE-2<br>Autologous<br>NCT04133636 | NDMM (BCMA)*<br>Transplant Eligible 1L<br>CARTITUDE-6<br>Autologous<br>NCT05257083 |

*In collaboration with Janssen, Pharmaceutical Companies of Johnson & Johnson. †Phase 1 IIT in China. ‡IND applications have been cleared by the U.S. FDA. §Subject to an exclusive license agreement with Novartis Pharma AG. Under the License Agreement, Legend Biotech will conduct a Phase 1 clinical trial for LB2102 in the U.S. and Novartis will conduct all other development for the licensed products.
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no assurance that the agents will receive health authority approval or become commercially available in any country for the uses being investigated. Additionally, as some programs are still confidential, certain candidates may not be included in this list.

ALL, acute lymphoblastic leukemia; BCMA, B-cell maturation antigen; DLL3, delta-like ligand 3; GPC3, glypican-3; GCC, guanylyl cyclase C; HCC, hepatocellular carcinoma; IIT, investigator-initiated trial; MM, multiple myeloma; ND, newly diagnosed; NHL, non-Hodgkin lymphoma; NSCLC, non small cell lung cancer; RRMM, relapsed or refractory multiple myeloma; SCLC, small cell lung cancer.

# Outlook: 2024 and Beyond

## NEAR-TERM GOALS

- Continue to increase manufacturing capacity and efficiency
- Begin manufacturing from Ghent facilities
- Complete enrollment of CARTITUDE-5 in 1H24
- Ongoing enrollment of CARTITUDE-6
- Advance early-stage pipeline programs
- Launch lenalidomide refractory 1-3 prior lines indication based on CARTITUDE-4, if approved by regulatory authorities. The PDUFA target action date is April 5, 2024. CHMP opinion, anticipated in 1Q 2024

## LONG-TERM GROWTH STRATEGY

- Move CARVYKTI® to earlier lines of therapy; increase penetration in the US and expand into global markets
- Focus on unmet medical needs in hematology/oncology
- Develop therapies with transforming potential
- Increase accessibility through lower cost and scalable manufacturing
- Build a global powerhouse by leveraging external collaborations